Sandoz Mulls Appeal As US Court Dismisses Amgen Enbrel Antitrust Complaint

A Decade After Approval, Sandoz’s US Erelzi Launch Remains Blocked

 
• By Dave Wallace
  
Sandoz’s etanercept complaint was dismissed by a Virginia district court (Shutterstock)

More from Legal & IP

More from Generics Bulletin